Long-term immunity after two doses of inactivated hepatitis a vaccine, in Argentinean children

Pediatric Infectious Disease Journal

Volumn 29, Issue 6, 2010, Pages 568-570

  López, Eduardo L ^a   Contrini, María M ^a   Mistchenko, Alicia ^a   Debbag, Roberto ^b  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b Sanofi Pasteur   (Argentina)

Author keywords

Argentina; Hepatitis A; Immunization; Pediatric

Indexed keywords

AVAXIM 80U; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; HEPATITIS A ANTIBODY; INACTIVATED VACCINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS A; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MALE; PATIENT SCHEDULING; PRIORITY JOURNAL; ADOLESCENT; ARGENTINA; BLOOD; CHI SQUARE DISTRIBUTION; FOLLOW UP; IMMUNOLOGY; NONPARAMETRIC TEST;

ADOLESCENT; ARGENTINA; CHI-SQUARE DISTRIBUTION; CHILD; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; STATISTICS, NONPARAMETRIC; VACCINES, INACTIVATED;

EID: 77953165493     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181d57a85     Document Type: Article

References (13)

1. Bell B, Feinstone S. Hepatitis A vaccines. In: Plotkin S, Orenstein W, eds. Vaccines. Philadelphia, PA: WB Saunders; 2004:269-297.
2. Lopez EL, Del C, X, Torrado LE, et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr Infect Dis J. 2001;20:48-52.
3. Dagan R, Greenberg D, Weber F. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up. Vaccine. 2005;23:5144-5148.
4. Lemon SM, Murphy PC, Provost PJ, et al. Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin. J Infect Dis. 1997;176: 9-19.
5. Miller WJ, Clark W, Hurni W, et al. Sensitive assays for hepatitis A antibodies. J Med Virol. 1993;41:201-204.
6. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55:1-23.
7. Lolekha S, Pratuangtham S, Punpanich W, et al. Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in Thai children: comparison of three vaccination schedules. J Trop Pediatr. 2003;49: 333-339.
8. Rendi-Wagner P, Korinek M, Winkler B, et al. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007;25:927-931.
9. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol. 2001;63:1-7.
10. Van Herck K, Van Damme P, Lievens M, et al. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol. 2004;72:194-196.
11. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362:1065-1071.
12. Hammitt LL, Bulkow L, Hennessy TW, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198:1776-1782.
13. Fan PC, Chang MH, Lee PI, et al. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine. 1998;16:232-235.